BeiGene: A Promising Biotech Company with Global Revenue Streams, According to Jefferies
Jefferies Analyst Bullish on BeiGene’s Global Revenue Streams Investors should keep an eye on biotech company BeiGene as it scales up its global revenue streams, according to Jefferies. Analyst Kelly Shi initiated coverage of the stock with a buy rating and assigned a price target of $287, suggesting shares stand to gain 49.2% in the…